- September 18, 2020
Commission urged to consider common regulatory framework for nanomedicines
The lack of a fit-for-purpose regulatory framework on nanomedicines and their “generics” poses risks for the safety of EU patients and the European Commission should urgently look to address this, the director of the European Alliance for Access to Safer Medicines (EAASM) has said.
Nanomedicine uses state-of-the-art nanotechnology like nanoparticles, nanorobots or nanoelectronic biosensors for diagnosing or treating diseases.
CONTINUE READING ON www.euractiv.com